is compounded semaglutide being discontinued Semaglutide: Legal & Safe 2026 Millions of people are taking

It is important to note that the use of GLP-1 RAs for weight loss or metabolic control in people who are subsequently diagnosed with cancer pose potential risks

Every GLP-1 agonist that has been tested in a cardiovascular outcomes trial has shown either benefit or neutrality, never harm

Upcoming Events

Cambi MPC, Baretta GAP, Magro DDO, Boguszewski CL, Ribeiro IB, Jirapinyo P, de Moura DTH

Despite Harvard Medical School research published in July 2024 showing diabetes patients prescribed semaglutide faced over four times higher NAION risk (and weight loss patients faced over seven times higher risk) Novo Nordisks current Ozempic and Wegovy labels still mention only generic vision changes without specifically identifying NAION or permanent blindness as known risks

(2.1) The maximum recommended daily dose is 100 mg of sitagliptin and 2000 mg of metformin HCl